Daniel Victor Ortigoza: Apixaban Shows Lower Bleeding Risk than Rivaroxaban in Acute VTE
Daniel Victor Ortigoza, 2nd Vice President of the Cardio-Oncology Committee at the Argentine Federation of Cardiology and President of the Arrhythmias and Electrophysiology Committee of the Argentine Federation of Cardiology, shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, published in The New England Journal of Medicine։
”Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Patients with DVT or PE were randomly assigned in a 1:1 ratio to rivaroxaban 15 mg twice daily for 21 days, apixaban 20 mg/day or apixaban 10 mg twice daily for 7 days, followed by apixaban 5 mg twice daily, both groups for 3 months.
The primary outcome (PO) was clinically relevant bleeding (CRB), a composite of clinically relevant non-major bleeding (CRNMB) or clinically relevant non-major bleeding according to the ISTH, and major bleeding (MB). The secondary outcomes (SO) were the individual components of the primary PE: recurrent DVT/PE.
CRB was observed in 3.3% with Apixaban versus 7.1% with Rivaroxaban (Relative Risk: 0.46; 95% CI, 0.33 to 0.65; P<0.001). MB 0.4% versus 2.4%; Relative Risk: 0.16; 95% CI, 0.06 to 0.40.
The percentage of DVT/PE recurrence was similar in the two treatment groups at 3 months
These data cannot be extrapolated to atrial fibrillation; the COBBRA-AF study on atrial fibrillation is currently underway.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté, Sam Schulman, Kerstin de Wit, James Douketis, Deepa Suryanarayan, Tony Wan, Erik Yeo, Genevieve Le Templier, Huyen A. Tran, Abbey Willcox, Helen J. Crowther, Ritam Prasad, Sudeep Shivakumar, Etimbuk Umana, Fionnuala Ni Ainle, Tobias Tritschler, Stefano Barco, Jean-Philippe Galanaud, Marc Blondon, Lisa Baumann Kreuziger, Susan Solymoss, Clive Kearon, Erin Thomas, Tim Ramsay, Gregoire Le Gal, Marc Rodger
Read the Full Article on The New England Journal of Medicine
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda